LensGen, a clinical stage opthalmic device company based in Irvine, California has developed a distruptive shape changing fluid intraocular lens (IOL) for treating cataracts and presbyopia. With its innovative Juvene IOL the company aims to bring to market this revolutionary device designed to restore full range of vision with high quality optics and improved safety ue to its biomimetic, capsule filling design. The Juvene IOL is cleared by FDA for pivotal US clinical study, supported by six-years OUS clinical experience with positive safety and efficacy outcomes. The LensGen Juvene IOL is also cleared by the Federal Institute for Drugs and Medical Devices (BfArM) to start a multicenter clinical study in Germany. On May 6, 20023, Sumit Garg, MD, from the Gavin Herbert Eye Instutute, University of California, Irvine presented 36 months clinical data at the American Society of Cataract and Refractive Surgery in San Diego.